Paul Ratner
Overview
Explore the profile of Paul Ratner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
153
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ratner P, Andrews C, Hampel F, Martin B, Mohar D, Bourrelly D, et al.
Allergy Asthma Clin Immunol
. 2017 Apr;
13:18.
PMID: 28392807
Background: Antagonism of chemoattractant receptor-homologous molecule on T-helper type-2 cells (CRTH2), a G-protein coupled receptor for prostaglandin D2, could be beneficial for treating allergic disorders. We present findings on the...
2.
Ratner P, van Bavel J, Mohar D, Jacobs R, Hampel F, Howland W, et al.
Ann Allergy Asthma Immunol
. 2015 Jan;
114(2):141-7.
PMID: 25624132
Background: Allergic rhinitis (AR) is an inflammatory condition of the nasal mucosa characterized by symptoms of nasal discharge, itching, sneezing, and congestion. Ocular symptoms are commonly associated with AR and...
3.
Georges G, Kim K, Ratner P, Segall N, Qiu C
Allergy Asthma Proc
. 2014 Apr;
35(2):163-70.
PMID: 24717794
Intranasal corticosteroids are the most effective medication class for controlling allergic rhinitis (AR) symptoms. However, limited data are available on their effects on basal hypothalamic-pituitary-adrenal (HPA) axis function in children....
4.
Meltzer E, Ratner P, Bachert C, Carr W, Berger W, Canonica G, et al.
Int Arch Allergy Immunol
. 2013 May;
161(4):369-77.
PMID: 23652808
Background: It is unclear what constitutes a clinically meaningful response for allergic rhinitis (AR) outcomes. The objectives of these post hoc analyses were (1) to define a clinically meaningful response...
5.
Carr W, Ratner P, Munzel U, Murray R, Price D, Canonica G, et al.
Allergy Asthma Proc
. 2012 Nov;
33(6):450-8.
PMID: 23127291
Intranasal corticosteroids are considered the most effective therapy for moderate-to-severe seasonal allergic rhinitis (SAR) and recommended first line in guidelines. It is uncertain whether intranasal antihistamines have comparable efficacy. This...
6.
Meltzer E, LaForce C, Ratner P, Price D, Ginsberg D, Carr W
Allergy Asthma Proc
. 2012 Aug;
33(4):324-32.
PMID: 22856633
Many patients with allergic rhinitis (AR) have uncontrolled symptoms despite available treatment options. This study was designed to evaluate the efficacy and safety of MP29-02 (a novel intranasal formulation of...
7.
Harrison L, Novak C, Needham M, Ratner P
J Aerosol Med Pulm Drug Deliv
. 2011 Jun;
24(5):245-52.
PMID: 21671752
Background: This report presents results of the first human study of a new dry powder inhaler (DPI-C). DPI-C uses reverse flow cyclone technology to retain larger particles in the device...
8.
Ratner P, Wingertzahn M, Herzog R, Huang H, Desai S, Maier G, et al.
Pulm Pharmacol Ther
. 2011 Apr;
24(4):426-33.
PMID: 21501692
Ciclesonide hydrofluoroalkane nasal aerosol (CIC-HFA) is currently in development for treatment of allergic rhinitis. This Phase I study evaluated the pharmacokinetics, pharmacodynamics, safety, and tolerability of CIC-HFA in healthy subjects...
9.
Ratner P, Jacobs R, Mohar D, Huang H, Desai S, Hinkle J
Ann Allergy Asthma Immunol
. 2010 Dec;
105(6):471-9.
PMID: 21130386
Background: A hypotonic aqueous nasal spray of ciclesonide is indicated for the treatment of allergic rhinitis (AR). A new nasal aerosol formulation of ciclesonide containing a hydrofluoroalkane propellant delivered via...
10.
Hampel F, Ratner P, Haeusler J
Allergy Asthma Proc
. 2010 Sep;
31(4):290-5.
PMID: 20819318
Allergic rhinitis (AR) and chronic idiopathic urticaria (CIU) are common causes of substantial illness and disability in preschool children. Antihistamines are commonly used to treat preschool children with these conditions,...